Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Krakow
Clinical trial register · Poland

Clinical Trials in Krakow, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2709 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:19 UTC
2709
Studies in scope
all four open statuses
1380
Recruiting now
open to new participants
510
Lead sponsors
across recruiting studies
Top sites
Warsaw 1318 Krakow 881 Poznan 697 Gdansk 663 Lodz 618
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca70 Eli Lilly and Company40 Hoffmann-La Roche39 Janssen Research & Development, LLC37 Merck Sharp & Dohme LLC36 Jagiellonian University32 Pfizer30 AbbVie25 Novartis Pharmaceuticals21 Sanofi21 Bristol-Myers Squibb16 Novo Nordisk A/S16 Takeda15 Amgen15 argenx12 GlaxoSmithKline11 Genmab11 BeOne Medicines10 Incyte Corporation10 Regeneron Pharmaceuticals10 UCB Biopharma SRL10 Acerta Pharma BV9 Boehringer Ingelheim8 Celgene7 Ipsen6 Show all 276
Site location
Warsaw1318 Krakow881 Poznan697 Gdansk663 Lodz618 Wroclaw526 Bydgoszcz525 Lublin525 Katowice510 Bialystok388 Olsztyn190 Rzeszów183 Szczecin183 Gdynia167 Gliwice121 Kielce117 Torun111 Opole106 Koszalin84 Siedlce81 Zabrze69 Elblag67 Otwock56 Przemyśl55 Chorzów53 Show all 264
All 264 locations
Target enrolment
to

Trials with a site in Krakow

881 of 2709 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Not yet open
Eli Lilly and Company
Phase 3
3,000
Bialystok, Krakow, Lublin, Piotrkow Trybunalski
2026-12
Not yet open
Novo Nordisk A/S
Phase 3
1,408
Grodzisk Mazowiecki, Ostrów Mazowiecka, Warsaw, Gdynia, Elblag, Gdansk, Krakow, Lodz
2026-11-11
Not yet open
A Study of Bimagrumab in Participants With HFpEF
NCT07920887Heart Failure, Diastolic, Diastolic Heart Failure, Heart Failure, Normal Ejection Fraction, Heart Failure, Preserved Ejection Fraction
DrugBimagrumab
Eli Lilly and Company
Phase 2
540
Krakow, Wroclaw
2026-11
Not yet open
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
NCT07873931Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
Bristol-Myers Squibb
Phase 1
60
Bydgoszcz, Krakow, Poznan
2026-10-30
Recruiting
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
NCT07473700Hypertension, Pulmonary, Lung Diseases, Interstitial
Tectonic Operating Company, Inc.
Phase 2
25
Krakow, Lublin, Wroclaw
2026-10-30
Not yet open
Wockhardt
Phase 3
324
Lublin, Opole, Krakow, Zabrze
2026-10-28
Not yet open
RBD1119 in Coronary Artery Disease (CAD)
NCT07884136Stable Coronary Artery Disease
DrugRBD1119
Ribocure Pharmaceuticals AB
Phase 2
200
Gdynia, Grodzisk Mazowiecki, Krakow, Lubin, Lublin, Warsaw, Zamość
2026-10-16
Recruiting
Idorsia Pharmaceuticals Ltd.
Phase 2
30
Katowice, Krakow, Osielsko
2026-10-06
Active, closed
Adapting the Sensory Environment to Reduce Stress in Children With Autism During Dental Visits
NCT07887243Autism, Autism Disorders and Maternal Stress, Sensory Integration Disorder, Stress Biomarkers
Jagiellonian University
Not applicable
40
Krakow
2026-10-01
Not yet open
Vortosiran in Atrial Fibrillation
NCT07870889Non-valvular Atrial Fibrillation (AF)
DrugsVortosiran·Apixaban
Ribocure Pharmaceuticals AB
Phase 2
150
Katowice, Krakow, Raszyn, Skorzewo, Warsaw, Wroclaw
2026-10-01
Not yet open
Vortosiran for VTE Prevention
NCT07850453Venous Thromboembolism (VTE), Cancer, Pulmonary Embolism (Diagnosis)
DrugVortosiran
Ribocure Pharmaceuticals AB
Phase 2
150
Gdynia, Grodzisk Mazowiecki, Krakow, Otwock, Poznan, Siedlce, Skorzewo, Szczecin
2026-10
Recruiting
Akeso
Phase 3
900
Krakow, Poznan, Warsaw
2026-09-24
Recruiting
Takeda
Observational
94
Krakow, Lodz, Warsaw, Zabrze
2026-09-24
Recruiting
AstraZeneca
Phase 3
750
Gdansk, Gliwice, Kielce, Krakow, Lublin, Wroclaw
2026-09-24
Recruiting
Pfizer
Phase 3
920
Milówka, Bialystok, Bydgoszcz, Dziekanów Leśny, Katowice, Krakow, Tarnów, Trzebnica
2026-09-22
Not yet open
Nutricia Research
Not applicable
68
Krakow
2026-09-15
Recruiting
AstraZeneca
Phase 3
1,330
Gdansk, Koszalin, Krakow, Lodz, Olsztyn, Poznan, Warsaw, Wroclaw
2026-09-15
Recruiting
CSL Behring
Phase 3
63
Torun, Krakow, Gliwice, Katowice, Skorzewo (Poznan)
2026-09-15
Recruiting
Vividion Therapeutics, Inc.
Phase 2
140
Skórzewo, Krakow, Wroclaw, Otwock, Siedlce, Warsaw, Opole, Przemyśl
2026-09-11
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365Geographic Atrophy
DrugSTL303
Sitala Bio LTD
Phase 2
300
Bielsko-Biala, Bydgoszcz, Katowice, Krakow, Olsztyn, Poznan, Warsaw, Wałbrzych
2026-09-11
Recruiting
Michał Kania
Not applicable
36
Krakow
2026-09-11
Recruiting
Takeda
Phase 3
324
Poznan, Torun, Krakow, Warsaw, Chorzów, Katowice, Lodz
2026-09-10
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Bydgoszcz, Chorzów, Gdansk, Katowice, Kielce, Krakow, Lublin, Szczecin
2026-09-09
Recruiting
Incyte Corporation
Phase 3
426
Gdansk, Katowice, Krakow, Lodz, Warsaw, Wałbrzych
2026-09-08
Recruiting
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Phase 4
8,100
Krakow
2026-09-02
Recruiting
Quality of Recovery-15 After Opioid-free Versus Opioid-based General Anesthesia in Major Urological Surgery
NCT07665463Postoperative Recovery, Anesthesia, General, Analgesics, Opioid, Urologic Surgical Procedure
Jagiellonian University
Not applicable
200
Krakow
2026-09-02
Recruiting
Jagiellonian University
Not applicable
200
Krakow
2026-09-02
Recruiting
Jagiellonian University
Not applicable
200
Krakow
2026-09-02
Not yet open
The Efficacy and Safety Study of 2107 Injection in Subjects With Mild to Moderate Knee Osteoarthritis
NCT07746843Mild Knee Osteoarthritis, Moderate Knee Osteoarthritis
BioRegen Biomedical (Changzhou) Co., Ltd
Not applicable
286
Krakow
2026-09-01
Not yet open
Multi-Food Oral Immunotherapy for Peanut and Tree Nuts
NCT07764159Food Allergies, Food Allergy in Children, Peanut Allergies, Tree Nut Allergies
Medical University of Warsaw
Not applicable
39
Poznan, Krakow, Dziekanów Leśny, Warsaw
2026-09
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
3,003
Biała Podlaska, Bydgoszcz, Częstochowa, Gdansk, Gdynia, Katowice, Krakow, Lodz
2026-08-31
Recruiting
AstraZeneca
Phase 3
1,072
Bydgoszcz, Katowice, Kielce, Krakow, Lodz, Ossy, Warsaw
2026-08-31
Recruiting
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07845487Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
DrugPALI-2108
Palisade Bio
Phase 2
204
Bydgoszcz, Elblag, Katowice, Kielce, Krakow, Kłodzko, Lodz, Lublin
2026-08-28
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
1,560
Biała Podlaska, Bydgoszcz, Częstochowa, Gdansk, Gdynia, Katowice, Krakow, Lodz
2026-08-28
Recruiting
Kardigan, Inc.
Phase 3
332
Gdansk, Krakow, Lodz, Warsaw
2026-08-26
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Bialystok, Częstochowa, Gdynia, Katowice, Krakow, Poznan, Przemyśl, Radzionków
2026-08-24
Recruiting
Vicora, Inc.
Not applicable
10
Poznan, Krakow
2026-08-21
Recruiting
AstraZeneca
Phase 3
1,500
Bialystok, Elblag, Gdynia, Katowice, Krakow, Legnica, Lodz, Poznan
2026-08-20
Recruiting
AstraZeneca
Phase 3
2,500
Bialystok, Elblag, Gdynia, Katowice, Krakow, Legnica, Lodz, Poznan
2026-08-19
Recruiting
Eli Lilly and Company
Phase 3
1,000
Bialystok, Bielsko-Biala, Bydgoszcz, Gdansk, Krakow, Leszno, Lodz, Olkusz
2026-08-14
Recruiting
Takeda
Observational
110
Poznan, Bydgoszcz, Krakow, Lublin, Warsaw, Opole, Przemyśl, Bialystok
2026-08-13
Recruiting
Alkermes, Inc.
Phase 3
150
Krakow
2026-08-13
Recruiting
Eli Lilly and Company
Phase 2
606
Bialystok, Krakow
2026-08-07
Recruiting
Xyra, LLC
Phase 2
100
Gdynia, Krakow, Rzeszów, Warsaw
2026-08-06
Recruiting
Novartis Pharmaceuticals
Phase 3
188
Tarnów, Bialystok, Krakow, Lublin, Piaseczno, Torun
2026-08-04
Recruiting
Boehringer Ingelheim
Phase 3
448
Bialystok, Bydgoszcz, Krakow, Poznan, Warsaw
2026-07-27
Recruiting
UCB BIOSCIENCES, Inc.
Phase 3
200
Gdansk, Krakow
2026-07-14
Recruiting
AstraZeneca
Phase 3
600
Bialystok, Częstochowa, Kielce, Krakow, Lodz, Poznan, Radom, Warsaw
2026-07-08
Recruiting
AstraZeneca
Phase 3
1,200
Bialystok, Krakow, Lodz, Lublin, Poznan, Radom, Warsaw
2026-07-06
Recruiting
Prilenia
Phase 3
400
Krakow, Warsaw
2026-07-01
Recruiting
AstraZeneca
Phase 3
4,500
Bialystok, Bydgoszcz, Kielce, Krakow, Lodz, Lublin, Poznan, Radom
2026-06-29
Recruiting
Ravulizumab Outcomes in Polish Patients With aHUS
NCT07399730Atypical Hemolytic Uremic Syndrome
DrugRavulizumab
AstraZeneca
Observational
80
Gdansk, Katowice, Krakow, Lodz, Poznan, Warsaw, Wroclaw
2026-06-24
Recruiting
Hoffmann-La Roche
Phase 3
380
Krakow, Gda?sk, Późna, Szczecin, Warsaw, Wroc?aw
2026-06-23
Recruiting
A Study of ARC-02 in B-cell NHL
NCT07691606B-cell Non Hodgkin Lymphoma
DrugRituximab
Taiho Oncology, Inc.
Phase 1
140
Katowice, Krakow, Skorzewo, Warsaw
2026-06-22
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
960
Krakow, Warsaw
2026-06-22
Recruiting
AstraZeneca
Phase 3
150
Gdansk, Konin, Krakow, Lodz, Lublin, Poznan, Przemyśl, Wroclaw
2026-06-15
Recruiting
Pfizer
Phase 3
1,200
Milówka, Dziekanów Leśny, Krakow, Tarnów, Trzebnica
2026-06-15
Recruiting
Eikon Therapeutics
Phase 2/3
750
Krakow
2026-06-15
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Bialystok, Krakow, Lodz, Poznan, Rzeszów, Warsaw
2026-06-11
Recruiting
Panuri Performance Study
NCT07587866Pancreatic Ductal Adenocarcinoma (PDAC)
Urteste S.A
Observational
1,100
Dąbrowa Tarnowska, Gdansk, Grudziądz, Iława, Krakow, Lodz, Lublin, Malbork
2026-06-10
Recruiting
argenx
Phase 3
230
Krakow, Katowice, Bydgoszcz, Chrzanów, Lublin, Warsaw, Zamość
2026-06-10
By invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Bydgoszcz, Krakow, Kłodzko, Lodz, Opole, Poznan, Rzeszów, Sopot
2026-06-08
Recruiting
AstraZeneca
Phase 2
80
Bydgoszcz, Krakow, Lodz, Lublin, Warsaw
2026-06-04
Recruiting
Prevention With Ismigen of RTIs in Kids
NCT07578012Respiratory Tract Infections (RTI), Healthy Children
Lallemand Pharma AG
Phase 4
224
Bialystok, Bydgoszcz, Krakow, Lublin, Oświęcim, Poznan, Tarnów
2026-06-01
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
Krakow, Skorzewo
2026-05-28
Recruiting
Amgen
Phase 3
304
Bydgoszcz, Krakow, Olsztyn
2026-05-27
Recruiting
UCB Biopharma SRL
Phase 3
120
Katowice, Krakow, Lublin, Warsaw
2026-05-27
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Bydgoszcz, Krakow, Lublin, Olsztyn, Opole, Rzeszów, Szczecin, Torun
2026-05-23
Recruiting
Genetic, Microbiological and Behavioral Factors in Obesity
NCT07650149Obesity & Overweight, Obesity, Genetics
Jan Kochanowski University
Observational
200
Krakow, Warsaw
2026-05-23
Recruiting
BeOne Medicines
Phase 3
1,056
Bialystok, Gdynia, Kielce, Krakow, Opole, Otwock, Warsaw
2026-05-22
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Bydgoszcz, Chorzów, Krakow, Lublin, Olsztyn, Opole, Rzeszów, Szczecin
2026-05-22
Recruiting
Takeda
Phase 3
300
Wroclaw, Krakow, Warsaw, Katowice, Skorzewo
2026-05-21
Recruiting
Hoffmann-La Roche
Phase 2/3
650
?ód?, Katowice, Krakow, Olsztyn, Opole, Późna, Tomaszów Mazowiecki, Wroc?aw
2026-05-21
Recruiting
Novo Nordisk A/S
Phase 3
2,500
Bialystok, Bydgoszcz, Dębica, Katowice, Krakow, Poznan, Rzeszów, Warsaw
2026-05-21
Recruiting
Multicenter Study for External Validation of the TB-NET Score
NCT07903532Tumor Burden, Neuroendocrine (NE) Tumors
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Observational
400
Krakow
2026-05-12
Recruiting
AstraZeneca
Observational
2,150
Lublin, Krakow, Radom, Bialystok, Częstochowa, Poznan, Warsaw, Lodz
2026-05-06
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Gdansk, Krakow
2026-05-06
Recruiting
Novo Nordisk A/S
Phase 3
300
Wroclaw, Gdansk, Krakow, Poznan, Warsaw
2026-05-05
Recruiting
Novo Nordisk A/S
Phase 3
300
Wroclaw, Gdansk, Krakow, Poznan, Warsaw
2026-05-05
Recruiting
AstraZeneca
Phase 3
670
Gdansk, Krakow, Warsaw
2026-05-04
Recruiting
Pfizer
Phase 3
2,400
Krakow, Milówka, Bydgoszcz, Dziekanów Leśny, Poznan, Torun, Trzebnica, Wroclaw
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Katowice, Krakow, Lublin, Poznan, Siedlce, Szczecin, Warsaw, Zamość
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Katowice, Krakow, Lublin, Poznan, Siedlce, Szczecin, Warsaw, Zamość
2026-05-04
Recruiting
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
DrugMK-1045
Merck Sharp & Dohme LLC
Phase 1/2
280
Krakow, Warsaw, Gliwice, Katowice
2026-05-03
Recruiting
Enlivex Therapeutics Ltd.
Phase 2
182
Bytom, Katowice, Krakow, Poznan, Radom, Swidnica, Warsaw, Wroclaw
2026-05-01
Recruiting
BioNTech SE
Phase 3
736
Krakow, Warsaw
2026-04-22
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Bydgoszcz, Krakow, Rzeszów, Szczecin, Torun, Warsaw
2026-04-21
Recruiting
Ionis Pharmaceuticals, Inc.
Phase 3
20
Krakow, Warsaw
2026-04-21
Recruiting
Boehringer Ingelheim
Phase 2
405
Bydgoszcz, Krakow, Poznan, Warsaw, Wroclaw
2026-04-20
Recruiting
Novo Nordisk A/S
Phase 3
400
Bialystok, Bydgoszcz, Krakow, Warsaw
2026-04-20
Recruiting
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 3
420
Gdansk, Krakow, Poznan, Siedlce, Szczecin
2026-04-17
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
Katowice, Krakow, Skorzewo, Warsaw
2026-04-17
Recruiting
Visugromab in Cachexia International Trial
NCT07112196Cancer-associated Cachexia
DrugVisugromab
CatalYm GmbH
Phase 2/3
518
Katowice, Krakow, Lodz, Lublin, Warsaw, Wroclaw
2026-04-16
Recruiting
Eli Lilly and Company
Phase 2
65
Gdansk, Krakow, Ostrowiec Świętokrzyski, Wroclaw
2026-04-14
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
DrugLY4005130
Eli Lilly and Company
Phase 2
66
Gdansk, Krakow, Ostrowiec Świętokrzyski, Wroclaw
2026-04-14
Recruiting
AstraZeneca
Phase 3
245
Bydgoszcz, Częstochowa, Katowice, Krakow, Lodz, Lublin, Nadarzyn, Nowa Sól
2026-04-13
Recruiting
Novo Nordisk A/S
Phase 3
400
Bialystok, Bydgoszcz, Krakow, Warsaw
2026-04-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Skórzewo, Krakow, Siedlce, Warsaw, Gliwice
2026-04-09
Recruiting
Incyte Corporation
Phase 3
588
Gdansk, Krakow, Warsaw, Wroclaw
2026-04-09
Recruiting
MRM Health NV
Phase 2
204
Bydgoszcz, Katowice, Krakow, Poznan, Sopot, Warsaw, Wroclaw
2026-04-03
Recruiting
Grifols Therapeutics LLC
Phase 3
40
Bydgoszcz, Katowice, Krakow, Wroclaw
2026-04-02
Recruiting
Michał Pasierbek
Not applicable
120
Wroclaw, Lublin, Warsaw, Krakow, Gdansk, Zabrze, Olsztyn, Kielce
2026-04-01
Recruiting
TG Therapeutics, Inc.
Phase 2
350
Bydgoszcz, Katowice, Kielce, Krakow, Lodz, Olsztyn, Poznan, Warsaw
2026-04-01
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
DrugsTiespectus·Eylea·Aflibercept
EyeBiotech Ltd.
Phase 2/3
960
Bydgoszcz, Gdansk, Katowice, Krakow, Olsztyn, Tarnowskie Góry
2026-03-27
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Chorzów, Katowice, Kielce, Krakow, Lodz, Malbork, Nowy Targ, Poznan
2026-03-26
Recruiting
Yuhan Corporation
Phase 2
150
Poznan, Krakow, Tarnów, Wroclaw, Lublin, Opole, Bialystok, Katowice
2026-03-26
Recruiting
Merck Sharp & Dohme LLC
Phase 2
100
Krakow, Wroclaw, Warsaw, Szczecin
2026-03-24
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Krakow
2026-03-24
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Bialystok, Bydgoszcz, Gdynia, Krakow, Lublin, Opole, Tarnów, Tychy
2026-03-16
Not yet open
Wireless Assessment of Respiratory and Circulatory Distress - Europe
NCT07451249Patient Deterioration, Patient Monitoring, Clinical Deterioration
Eske Kvanner Aasvang
Not applicable
1,240
Krakow
2026-03-16
Recruiting
Takeda
Phase 3
1,182
Bialystok, Bytom, Krakow, Nowa Sól, Opole, Poznan, Sochaczew, Torun
2026-03-11
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Krakow, Lublin, Malbork, Rzeszów, Warsaw, Zamość
2026-03-10
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Bydgoszcz, Krakow
2026-03-09
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Bydgoszcz, Bytom, Katowice, Krakow, Nadarzyn, Nowa Sól, Poznan, Płońsk
2026-03-05
Recruiting
Nura Bio
Phase 1/2
80
Krakow, Warsaw
2026-03-04
Recruiting
Poland-Italy Aortic Research Bridge Real World Registry
NCT07476196Abdominal Aortic Aneurysm
American Heart of Poland
Observational
200
Bialystok, Bielsko-Biala, Bytom, Chrzanów, Ełk, Gdynia, Kielce, Krakow
2026-03-01
Not yet open
Advanced Endoscopic Resections for Rectal Neoplasms
NCT07410767Rectal Cancer, Rectal Adenocarcinoma, Rectal Adenoma, Rectal Neuroendocrine Neoplasm
Jagiellonian University
Observational
300
Krakow
2026-03-01
Recruiting
ShockFast Intravascular Lithotripsy Device for Treatment of Calcified Coronary Lesions
NCT07407738Coronary Arterial Disease, Calcified Coronary Artery Disease
Shunmei Medical
Not applicable
120
Katowice, Krakow, Lubin, Wroclaw
2026-02-16
Recruiting
Boehringer Ingelheim
Phase 3
286
Krakow, Lodz, Poznan, Szczecin, Warsaw, Wroclaw
2026-02-16
Recruiting
Universidad Complutense de Madrid
Not applicable
30
Krakow, Nowy Targ
2026-02-15
Recruiting
Kardigan, Inc.
Phase 2/3
332
Gdansk, Krakow, Lodz, Warsaw
2026-02-13
Recruiting
Pfizer
Phase 2/3
1,156
Katowice, Krakow, Tarnów, Warsaw, Wroclaw, Ostrowiec Świętokrzyski
2026-02-11
Recruiting
Eli Lilly and Company
Phase 3
1,000
Bialystok, Bielsko-Biala, Gdansk, Krakow, Poznan, Szczecin, Wroclaw, Zabrze
2026-02-09
Active, closed
Janssen Research & Development, LLC
Phase 2
168
Brzozów, Kielce, Krakow, Lodz, Lublin, Poznan, Torun, Wroclaw
2026-02-08
Active, closed
Corxel Pharmaceuticals
Phase 2
251
Poznan, Bydgoszcz, Krakow, Tarnów, Wroclaw, Lodz, Warsaw, Gdansk
2026-02-06
Recruiting
Eli Lilly and Company
Phase 3
1,980
Bialystok, Krakow, Lodz, Lublin, Poznan, Wroclaw, Zabrze
2026-02-06
Recruiting
AstraZeneca
Phase 3
2,130
Gdansk, Koszalin, Krakow, Lublin, Olsztyn, Warsaw
2026-02-03
Recruiting
Exciva GmbH
Phase 2/3
300
Poznan, Krakow, Wroclaw, Lublin, Sochaczew, Warsaw, Katowice, Zabrze
2026-02-02
Recruiting
Prilenia
Phase 3
500
Bydgoszcz, Krakow, Warsaw
2026-02-01
Recruiting
Genmab
Phase 2
240
Gdansk, Krakow, Lodz, Poznan
2026-01-30
Active, closed
Jagiellonian University
Observational
700
Krakow
2026-01-29
Recruiting
BeOne Medicines
Phase 3
500
Brzozów, Katowice, Krakow, Lublin, Wroclaw
2026-01-22
Recruiting
Eikon Therapeutics
Phase 1/2
160
Szczecin, Krakow, Lodz
2026-01-20
Recruiting
Sanofi
Phase 3
751
Bydgoszcz, Elblag, Katowice, Krakow, Kłodzko, Lublin, Opole, Poznan
2026-01-16
Active, closed
Janssen Research & Development, LLC
Phase 2
157
Bialystok, Bydgoszcz, Elblag, Krakow, Lublin, Nadarzyn, Olsztyn, Torun
2026-01-15
Recruiting
Celldex Therapeutics
Phase 3
240
Gdansk, Krakow, Lodz, Lublin, Opole, Oświęcim, Rzeszów, Tarnów
2026-01-15
Active, closed
Kailera
Phase 3
1,270
Bydgoszcz, Torun, Krakow, Lublin, Siedlce, Warsaw, Bialystok, Gdynia
2026-01-12
Active, closed
Hoffmann-La Roche
Phase 2
120
Katowice, Gdynia, Krakow, Rzeszów, Warsaw
2026-01-08
Recruiting
Insmed Incorporated
Phase 3
344
Bialystok, Krakow, Lublin, Warsaw
2026-01-07
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Poznan, Krakow, Jelenia Góra, Warsaw, Wieliszew, Prabuty, Bydgoszcz
2026-01-02
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Krakow, Warsaw, Wieliszew, Opole, Brzozów, Gdansk, Gliwice, Koszalin
2025-12-31
Active, closed
Kailera
Phase 3
1,270
Krakow, Warsaw, Gdynia, Chorzów, Bydgoszcz, Wroclaw, Kielce
2025-12-30
Recruiting
Norgine
Phase 3
212
Torun, Krakow, Warsaw, Bialystok, Gdansk, Zabrze
2025-12-29
Active, closed
UCB Biopharma SRL
Phase 2
165
Chorzów, Katowice, Krakow, Lodz, Sosnowiec, Tarnów, Warsaw, Wroclaw
2025-12-29
Recruiting
argenx
Observational
70
Bydgoszcz, Krakow, Katowice, Warsaw
2025-12-19
Active, closed
Pfizer
Phase 3
3,578
Bialystok, Bydgoszcz, Chojnice, Częstochowa, Gdansk, Gdynia, Katowice, Krakow
2025-12-19
Active, closed
Kailera
Phase 3
2,530
Poznan, Torun, Krakow, Siedlce, Warsaw, Skierniewice, Zamość
2025-12-18
Recruiting
AstraZeneca
Phase 2
320
Krakow, Torun, Warsaw, Wroclaw
2025-12-15
Recruiting
Jagiellonian University
Observational
200
Krakow
2025-12-15
Recruiting
Eli Lilly and Company
Phase 3
1,035
Bialystok, Bydgoszcz, Elblag, Krakow, Lodz, Lublin, Ruda Śląska, Zabrze
2025-12-15
Recruiting
Jagiellonian University
Observational
200
Krakow
2025-12-15
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Bydgoszcz, Koszalin, Krakow, Skórzewo, Sosnowiec, Warsaw, Wrocaw
2025-12-12
Recruiting
Pfizer
Phase 3
800
Katowice, Koszalin, Krakow, Opole, Poznan
2025-12-11
Recruiting
Jagiellonian University
Observational
60
Krakow
2025-12-10
Recruiting
UCB Biopharma SRL
Phase 1
392
Bialystok, Bydgoszcz, Bytom, Elblag, Krakow, Lodz, Lublin, Nowa Sól
2025-12-10
Recruiting
AbbVie
Phase 2/3
490
Poznan, Krakow, Warsaw, Gdansk, Sosnowiec
2025-12-10
Recruiting
Hoffmann-La Roche
Phase 2
160
Bytom, Elbl?g, Krakow, Lublin, Nowa Sól, Warsaw, Wroclaw
2025-12-05
By invitation
RVU120 Rollover Study
NCT06987058Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
DrugsRVU120·Ruxolitinib
Ryvu Therapeutics SA
Phase 2
14
Chorzów, Gdansk, Katowice, Krakow, Wroclaw
2025-12-04
Recruiting
AstraZeneca
Phase 3
1,100
Koszalin, Krakow, Lodz, Olsztyn, Warsaw
2025-12-04
Recruiting
Bristol-Myers Squibb
Phase 3
650
Poznan, Bydgoszcz, Chorzów, Katowice, Krakow, Lublin, Sochaczew, Wroclaw
2025-12-02
Recruiting
Pfizer
Phase 3
450
Krakow, Lublin, Warsaw, Chorzów, Lodz, Ostrowiec Świętokrzyski
2025-12-02
Recruiting
Eli Lilly and Company
Phase 3
7,140
Bialystok, Bydgoszcz, Elblag, Krakow, Lodz, Lublin, Radom, Ruda Śląska
2025-12-01
Not yet open
Milosz Pietrus
Not applicable
45
Krakow
2025-12-01
Recruiting
Pregnancy and Fibrin Clot Properties
NCT07275476Fibrin Blood Clot, Pregnancy, Pregnancy Complicated by Cardiovascular Disorders as Postpartum Condition, Delivered During Previous Episode
Jagiellonian University
Observational
100
Krakow
2025-11-28
Recruiting
Hoffmann-La Roche
Phase 3
250
Krakow, Bielsko-Biala, Bydgoszcz, Gliwice, Lódz, Lublin, Olsztyn
2025-11-27
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 2
78
Gdansk, Krakow, Warsaw
2025-11-26
Recruiting
Merck Sharp & Dohme LLC
Phase 3
904
Skórzewo, Bydgoszcz, Krakow, Siedlce, Warsaw, Przemyśl, Koszalin
2025-11-26
Recruiting
Debiopharm International SA
Phase 3
119
Bydgoszcz, Gliwice, Krakow, Poznan, Wroclaw
2025-11-26
Recruiting
Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.
Phase 3
1,703
Bialystok, Bydgoszcz, Gdansk, Grudziądz, Katowice, Krakow, Lodz, Nowa Sól
2025-11-25
Recruiting
PhenoNet, Inc.
Phase 2
105
Krakow, Warsaw
2025-11-25
By invitation
Celldex Therapeutics
Phase 3
1,370
Bialystok, Częstochowa, Elblag, Gdansk, Katowice, Krakow, Lublin, Oświęcim
2025-11-25
Active, closed
Kymera Therapeutics, Inc.
Phase 2
200
Chorzów, Gdansk, Gdynia, Krakow, Lublin, Rzeszów, Szczecin, Warsaw
2025-11-24
Recruiting
Hoffmann-La Roche
Phase 3
900
Bia?ystok, Bydgoszcz, Gda?sk, Katowice, Krakow, Lublin, Oświęcim, Rzeszów
2025-11-24
Recruiting
Pfizer
Phase 2
165
Krakow, Szczecin, Gdansk, Katowice, Kielce
2025-11-20
Recruiting
UCB Biopharma SRL
Phase 3
320
Bialystok, Gdansk, Katowice, Krakow, Lodz, Poznan, Rzeszów, Szczecin
2025-11-14
Recruiting
Incyte Corporation
Phase 3
250
Gdansk, Katowice, Krakow, Lublin, Nowa Sól, Osielsko, Rzeszów, Szczecin
2025-11-13
Active, closed
Hoffmann-La Roche
Phase 3
1,060
?cinawa, ?ory, ?ód?, B?dzin, Bia?ystok, Gdansk, Krakow, Późna
2025-11-12
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Krakow, Bydgoszcz, Chojnice, Katowice, Lodz, Lublin, Rzeszów, Skorzewo
2025-11-11
Recruiting
AstraZeneca
Phase 3
420
Kielce, Krakow, Lodz, Lublin, Wroclaw
2025-11-11
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Krakow, Wroclaw, Warsaw, Otwock, Rzeszów, Gdansk, Brzozów, Lodz
2025-11-03
Recruiting
BioNTech SE
Phase 3
558
Chorzów, Gdansk, Krakow, Lodz, Lublin, Poznan, Warsaw
2025-10-30
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
Bydgoszcz, Gdansk, Krakow, Lodz, Olsztyn
2025-10-28
Recruiting
Hoffmann-La Roche
Phase 3
600
Bystra, Gda?sk, Krakow, Lublin, Olsztyn, Poznan, Radom, Warsaw
2025-10-24
Recruiting
Eli Lilly and Company
Phase 3
1,630
Bialystok, Gdansk, Krakow, Poznan, Siedlce
2025-10-22
Recruiting
Eli Lilly and Company
Phase 2
531
Krakow, Poznan
2025-10-22
Recruiting
Pharvaris Netherlands B.V.
Phase 3
48
Krakow
2025-10-16
Recruiting
Nurix Therapeutics, Inc.
Phase 2
100
Katowice, Krakow, Skorzewo, Warsaw
2025-10-15
Active, closed
Gesynta Pharma AB
Phase 2
213
Bialystok, Bydgoszcz, Katowice, Krakow, Lublin, Siedlce, Skorzewo, Szczecin
2025-10-15
Recruiting
Sanofi
Phase 3
980
Elblag, Katowice, Krakow, Lodz, Poznan, Rzeszów, Sopot, Staszów
2025-10-08
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Gdansk, Katowice, Krakow, Opole
2025-10-03
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Bydgoszcz, Krakow, Lublin, Nowy Targ, Olsztyn, Opole, Poznan, Rzeszów
2025-10-03
By invitation
Astria Therapeutics, Inc.
Phase 3
145
Krakow, Rzeszów
2025-10-01
Recruiting
AllRock Bio, Inc.
Phase 2
40
Krakow
2025-10-01
Active, closed
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)
NCT07210463Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
DrugXeomin
Merz Aesthetics GmbH
Phase 3
300
Krakow, Oświęcim, Lublin, Warsaw, Bialystok, Gdynia, Lodz, Ostrowiec Świętokrzyski
2025-10-01
Recruiting
Sanofi
Phase 3
980
Bydgoszcz, Elblag, Katowice, Krakow, Kłodzko, Lodz, Lublin, Nowy Targ
2025-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
896
Bydgoszcz, Katowice, Krakow, Lublin, Nowy Targ, Olsztyn, Opole, Poznan
2025-10-01
Recruiting
Pfizer
Phase 3
1,000
Poznan, Wroclaw, Szczecin, Koszalin, Krakow, Lublin, Rzeszów
2025-09-28
Recruiting
Sanofi
Phase 3
124
Krakow, Wroclaw, Gdansk
2025-09-26
Recruiting
Lohmann & Rauscher
Not applicable
150
Bialystok, Krakow, Lodz, Lublin, Ostróda, Wroclaw, Zabrze
2025-09-23
Recruiting
BioNTech SE
Phase 1/2
880
Gdansk, Krakow, Poznan, Tomaszów Mazowiecki
2025-09-22
Active, closed
Hoffmann-La Roche
Phase 3
1,101
Bydgoszcz, Katowice, Krakow, Lublin, Rzeszów, Warsaw, Wroc?aw, Zabrze
2025-09-17
Recruiting
Zydus Therapeutics Inc.
Phase 2
240
Krakow, Warsaw
2025-09-17
Recruiting
Sanofi
Phase 3
942
Poznan, Krakow, Lodz, Bialystok, Chęciny, Ostrowiec Świętokrzyski
2025-09-17
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
DrugEmpasiprubart
argenx
Phase 3
160
Katowice, Krakow, Warsaw
2025-09-16
Recruiting
Pfizer
Phase 3
140
Krakow, Wroclaw, Lublin, Warsaw, Katowice, Rzeszów, Lodz
2025-09-10
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Bielsko-Biala, Krakow, Otwock, Poznan, Rzeszów, Skorzewo, Tomaszów Mazowiecki, Warsaw
2025-09-08
By invitation
Jagiellonian University
Observational
80
Krakow
2025-09-08
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Bielsko-Biala, Bydgoszcz, Elblag, Grudziądz, Katowice, Komorniki, Krakow, Leszno
2025-09-02
Recruiting
Pulmonary Rehabilitation in Salt Chambers for Patients With COPD
NCT07122544COPD (Chronic Obstructive Pulmonary Disease)
University School of Physical Education, Krakow, Poland
Not applicable
80
Krakow
2025-09-01
Not yet open
Bedside Ultrasound to Monitor Lung Function and Blood Flow in Newborns Treated With Surfactant
NCT07070167Lung Ultrasound, Respiratory Distress Syndrome, Newborn
Chiesi Poland Sp. z o.o.
Observational
200
Krakow, Warsaw
2025-08-30
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Krakow, Lodz, Wroclaw
2025-08-28
Recruiting
BeOne Medicines
Phase 3
351
Krakow, Opole, Warsaw
2025-08-27
Recruiting
Relay Therapeutics, Inc.
Phase 3
540
Konin, Krakow, Lublin, Poznan, Rzeszów, Warsaw
2025-08-26
Recruiting
Marcin Barczynski
Not applicable
154
Krakow
2025-08-23
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Bydgoszcz, Katowice, Krakow, Lublin, Poznan, Rzeszów, Szczecin, Warsaw
2025-08-22
Active, closed
Merz Therapeutics GmbH
Phase 3
997
Bydgoszcz, Dębica, Gdynia, Katowice, Krakow, Lublin, Oświęcim, Poznan
2025-08-21
Active, closed
Merz Therapeutics GmbH
Phase 3
808
Bydgoszcz, Dębica, Gdynia, Katowice, Krakow, Lublin, Oświęcim, Poznan
2025-08-21
Active, closed
A Study of SPY072 in Rheumatic Disease
NCT07148414Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases
DrugSPY072
Spyre Therapeutics, Inc.
Phase 2
285
Krakow, Nowa Sól, Lodz, Warsaw, Opole, Gdynia, Warszawa, Elblag
2025-08-21
Recruiting
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease
Abcentra
Phase 2
240
Krakow, Wroclaw, Warsaw
2025-08-11
Active, closed
Novo Nordisk A/S
Phase 3
877
Krakow, Oświęcim, Tarnów, Legnica, Bydgoszcz, Gdansk, Lodz, Lublin
2025-08-11
Recruiting
AstraZeneca
Phase 3
700
Gdynia, Gliwice, Koszalin, Krakow, Piotrkow Trybunalski, Poznan, Rzeszów, Warsaw
2025-08-06
Recruiting
Pfizer
Phase 3
400
Bydgoszcz, Krakow, Wroclaw, Warsaw, Opole
2025-08-05
Recruiting
DCB vs. DES in Bifurcation Coronary Lesions
NCT06551662Coronary Artery Disease, DCB
Fondazione Ricerca e Innovazione Cardiovascolare ETS
Not applicable
321
Gdansk, Katowice, Krakow, Lubin, Lublin, Poznan, Rzeszów, Warsaw
2025-08-01
Recruiting
Crystalys Therapeutics
Phase 3
500
Poznan, Krakow, Wroclaw, Plońsk, Sochaczew, Warsaw, Bialystok, Gdynia
2025-08-01
Active, closed
Pfizer
Phase 3
208
Krakow, Wroclaw, Lublin, Warsaw, Bialystok, Katowice, Ossy, Rzeszów
2025-07-31
Recruiting
Comparison of Nissen-Sleeve and Gastric Bypass for GERD in Obese Patients
NCT07158008Gastro Esophageal Reflux, Severe Obesity, Bariatric Surgery
Jagiellonian University
Not applicable
560
Krakow
2025-07-31
Recruiting
Eli Lilly and Company
Phase 1/2
68
Katowice, Krakow, Skorzewo, Torun, Wroclaw
2025-07-30
Recruiting
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)
NCT07047703Axial Spondyloarthritis (AxSpA)
Grey Wolf Therapeutics
Phase 1/2
140
Krakow, Lublin, Poznan
2025-07-28
Recruiting
Celgene
Phase 3
400
Skórzewo, Krakow, Warsaw, Gdynia, Lodz
2025-07-28
Recruiting
Celcuity Inc
Phase 3
1,180
Siedlce, Bydgoszcz, Konin, Krakow, Lodz, Opole, Szczecin, Warsaw
2025-07-24
Recruiting
Pfizer
Phase 3
150
Krakow, Lublin, Warsaw, Chorzów, Katowice, Lodz, Ostrowiec Świętokrzyski
2025-07-24
Recruiting
Occupational Situation and Return to Work of Urological Patients
NCT07088536Bladder Cancer, Prostate Cancer, Renal Cancer, Urinary Stones
Jagiellonian University
Observational
2,000
Krakow
2025-07-21
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Gliwice, Katowice, Krakow, Warsaw, Wroclaw
2025-07-21
Recruiting
Bristol-Myers Squibb
Phase 3
426
Poznan, Bydgoszcz, Chorzów, Katowice, Krakow, Lublin, Sochaczew, Wroclaw
2025-07-16
Recruiting
Hoffmann-La Roche
Observational
700
Krakow, Lublin, Olsztyn, Poznan, Słupsk, Tomaszów Mazowiecki
2025-07-15
Recruiting
Takeda
Phase 3
347
Gmina Świecie, Krakow, Lodz, Wroclaw
2025-07-15
Active, closed
Bluefin Biomedicine, Inc.
Phase 2
225
Bialystok, Bydgoszcz, Chorzów, Gdansk, Grodzisk Mazowiecki, Krakow, Malbork, Ostrowiec Świętokrzyski
2025-07-15
Recruiting
University Hospital, Basel, Switzerland
Phase 2
150
Krakow
2025-07-15
Active, closed
Upstream Bio Inc.
Phase 2
666
Bydgoszcz, Poznan, Krakow, Lublin, Nowa Sól, Skierniewice, Sochaczew, Rzeszów
2025-07-02
Recruiting
Immune Cell Populations in the Endometrium
NCT06826365Infertility, Female, Recurrent Miscarriage, Gynecologic Disease
Jagiellonian University
Observational
50
Krakow
2025-07-01
Recruiting
MedSIR
Phase 2
200
Krakow, Legionowo
2025-06-30
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Paraplatin
Merck Sharp & Dohme LLC
Phase 3
2,400
Bydgoszcz, Krakow, Wałbrzych, Warsaw, Bialystok, Słupsk, Olsztyn, Koszalin
2025-06-30
Recruiting
Novo Nordisk A/S
Phase 2
200
Wroclaw, Lublin, Bialystok, Biała Podlaska, Bielsko-Biala, Krakow, Przemyśl, Warsaw
2025-06-30
Recruiting
Ipsen
Phase 2
132
Katowice, Krakow, Oświęcim, Pabianice, Warsaw, Wroclaw
2025-06-30
Active, closed
Immunovant Sciences GmbH
Phase 2
180
Bydgoszcz, Krakow, Lodz, Lublin, Poznan, Siedlce, Warsaw, Wołomin
2025-06-30
Recruiting
Novo Nordisk A/S
Phase 2
200
Wroclaw, Lublin, Bialystok, Szczecin, Bielsko-Biala, Krakow, Lodz, Przemyśl
2025-06-27
By invitation
MoonLake Immunotherapeutics AG
Phase 3
835
Bialystok, Chorzów, Gdansk, Katowice, Kielce, Krakow, Lodz, Lublin
2025-06-27
Recruiting
Regeneron Pharmaceuticals
Phase 3
2,000
Krakow, Lodz, Poznan
2025-06-25
Recruiting
Noradrenaline Versus Standard Blood Pressure Management for Perioperative Hypotension in Non-cardiac Surgery
NCT06885268Blood Pressure Management, Intraoperative Hypotension, Non-cardiac Surgery
Jagiellonian University
Phase 3
750
Katowice, Krakow, Olsztyn, Opole, Zabrze
2025-06-24
Recruiting
AbbVie
Phase 2
180
Bydgoszcz, Krakow, Warsaw, Elblag, Olsztyn
2025-06-20
Recruiting
GlaxoSmithKline
Phase 3
981
Poznan, Katowice, Bialystok, Bydgoszcz, Krakow, Rzeszów, Wroclaw
2025-06-20
Active, closed
AbbVie
Phase 3
573
Poznan, Bydgoszcz, Krakow, Wroclaw, Warsaw, Chojnice, Bytom, Szczecin
2025-06-17
Active, closed
Incyte Corporation
Phase 3
159
Gdansk, Katowice, Krakow, Lodz, Lublin, Szczecin, Torun, Warsaw
2025-06-17
Recruiting
Celgene
Phase 2
200
Bydgoszcz, Krakow, Oświęcim, Warsaw, Katowice, Gdansk, Słomniki, Lodz
2025-06-05
Recruiting
Boehringer Ingelheim
Phase 2
300
Bielsko-Biala, Bydgoszcz, Katowice, Krakow, Olsztyn, Poznan, Tarnowskie Góry, Warsaw
2025-06-05
Recruiting
AstraZeneca
Phase 3
15,100
Bialystok, Bydgoszcz, Gdansk, Gdynia, Jelenia Góra, Katowice, Kędzierzyn-Koźle, Krakow
2025-06-04
Recruiting
Sanofi
Phase 2
99
Wroclaw, Krakow, Lublin, Sopot, Warsaw
2025-06-03
Active, closed
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
NCT07037277HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C
DrugSofosbuvir-Velpatasvir
Atea Pharmaceuticals, Inc.
Phase 3
880
Krakow, Kłodzko, Lublin, Mysłowice, Warsaw, Wroclaw
2025-06-02
Recruiting
MediWound Ltd
Phase 3
216
Krakow, Lublin, Warsaw, Bialystok, Siemianowice Śląskie, Tychy, Lodz, Nowy Targ
2025-06-01
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Gdansk, Gliwice, Krakow, Poznan, Warsaw
2025-05-30
Recruiting
Medical Inventi S.A.
Not applicable
80
Krakow, Otwock
2025-05-29
Recruiting
Chiesi Poland Sp. z o.o.
Observational
120
Gdansk, Krakow, Lodz, Poznan, Warsaw, Wroclaw
2025-05-29
Active, closed
AstraZeneca
Phase 3
3,103
Bialystok, Gdansk, Gdynia, Katowice, Kędzierzyn-Koźle, Krakow, Lodz, Lublin
2025-05-28
Recruiting
Immunovant Sciences GmbH
Phase 3
231
Gdansk, Katowice, Krakow, Lublin, Warsaw
2025-05-27
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Bydgoszcz, Katowice, Krakow, Opole, Poznan, Rzeszów, Sopot, Staszów
2025-05-27
Active, closed
Sanofi
Phase 3
1,092
Bydgoszcz, Torun, Krakow, Trzebnica, Wroclaw, Warsaw, Łomianki, Siemianowice Śląskie
2025-05-22
Active, closed
Upstream Bio Inc.
Phase 2
396
Wroclaw, Krakow, Tarnów, Rzeszów, Bialystok, Gdansk, Ostrowiec Świętokrzyski
2025-05-21
Recruiting
Polish Registry of Percutaneous Coronary Intervention for Chronic Total Occlusions
NCT07330622Coronary Occlusion, Percutaneous Coronary Intervention
National Institute of Cardiology, Warsaw, Poland
Observational
1,000
Bialystok, Grodzisk Mazowiecki, Inowrocław, Katowice, Krakow, Lubin, Lublin, Nowy Sącz
2025-05-21
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
787
Krakow, Warsaw
2025-05-20
Recruiting
Boehringer Ingelheim
Phase 3
4,200
Bielsko-Biala, Bydgoszcz, Gdynia, Krakow, Legnica, Lodz, Lublin, Piaseczno
2025-05-20
Recruiting
Eli Lilly and Company
Phase 4
279
Krakow, Warsaw
2025-05-20
Recruiting
Pfizer
Phase 2
252
Poznan, Krakow, Tarnów, Wroclaw, Bychawa, Sosnowiec
2025-05-20
Recruiting
SecuraBio
Phase 3
124
Gdansk, Krakow, Warsaw
2025-05-19
Recruiting
AstraZeneca
Observational
50
Bydgoszcz, Gdansk, Katowice, Krakow, L DZ, Lublin, Poznan, Szczecin
2025-05-15
Recruiting
Jagiellonian University
Observational
20
Krakow
2025-05-14
Recruiting
Apogee Therapeutics, Inc.
Phase 2
350
Wroclaw, Lublin, Warsaw, Gdansk, Katowice, Sosnowiec, Szczecin, Krakow
2025-05-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Poznan, Bydgoszcz, Krakow, Siedlce, Warsaw, Katowice
2025-05-13
Recruiting
Hoffmann-La Roche
Phase 3
425
Bia?ystok, Bydgoszcz, Elblag, I?awa, Knurów, Krakow, Lodz, Lublin
2025-05-12
Active, closed
Sanofi
Phase 2
71
Poznan, Krakow, Wroclaw, Warsaw, Katowice
2025-05-12
Recruiting
Bambusa Therapeutics
Phase 1
286
Gdansk, Krakow
2025-05-08
Recruiting
Biogen
Phase 3
454
Krakow, Lodz, Gdansk, Szczecin
2025-05-08
Active, closed
Cartesian Therapeutics
Phase 3
128
Krakow
2025-05-06
Recruiting
Takeda
Phase 3
59
Krakow, Lublin, Warsaw, Gdansk
2025-05-06
Active, closed
Hoffmann-La Roche
Phase 2
285
Krakow, Gdansk, Lublin, Warsaw
2025-05-05
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Poznan, Gorlice, Krakow, Wroclaw, Lublin, Bydgoszcz, Katowice, Prabuty
2025-04-24
Recruiting
Vanda Pharmaceuticals
Phase 3
420
Bydgoszcz, Gdansk, Krakow, Poznan, Wroclaw
2025-04-21
Active, closed
Merck Sharp & Dohme LLC
Phase 2
440
Krakow, Lublin, Bialystok
2025-04-16
Active, closed
Janssen Research & Development, LLC
Phase 3
752
Bialystok, Elblag, Katowice, Krakow, Lodz, Olsztyn, Poznan, Skierniewice
2025-04-15
Recruiting
Hoffmann-La Roche
Not applicable
270
Gdansk, Krakow, Kraśnik, Lublin, Nadarzyn, Warsaw
2025-04-14
Recruiting
Merck Sharp & Dohme LLC
Phase 2
594
Skórzewo, Krakow, Nowy Sącz, Wałbrzych, Warsaw, Gdansk, Katowice
2025-04-11
Recruiting
BeOne Medicines
Phase 3
250
Brzozów, Katowice, Krakow, Lodz, Lublin, Wroclaw
2025-04-10
Recruiting
Epygenix
Phase 3
260
Krakow, Wroclaw, Warsaw
2025-04-09
Active, closed
Arrowhead Pharmaceuticals
Phase 3
710
Elblag, Gdynia, Katowice, Krakow, Lodz, Malbork, Szczecin, Warsaw
2025-04-09
Recruiting
Hoffmann-La Roche
Phase 3
450
?ód?, Bialystok, Konin, Koszalin, Krakow, Lublin, Późna, Rzeszów
2025-04-09
Active, closed
Philip Morris Products S.A.
Not applicable
290
Bialystok, Kajetany, Krakow, Lodz, Sochaczew, Warsaw, Wroclaw
2025-04-02
Active, closed
Hoffmann-La Roche
Phase 2
162
Gdynia, Katowice, Krakow, Rzeszów, Warsaw
2025-04-01
Recruiting
Pfizer
Phase 3
674
Poznan, Krakow, Wroclaw, Lublin, Nowa Sól, Warsaw, Katowice, Sosnowiec
2025-04-01
Recruiting
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06980116Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL)
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1
85
Krakow, Lodz, Lublin, Skórzewo
2025-03-31
Recruiting
Eli Lilly and Company
Phase 2
200
Bialystok, Gdansk, Krakow, Lodz, Lublin, Tarnów, Warsaw, Wroclaw
2025-03-28
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
270
Poznan, Krakow, Warsaw, Koszalin
2025-03-25
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
206
Wroclaw, Lublin, Krakow, Rzeszw, Malbork, Bialystok-Podlaskie, Katowice, Warsaw
2025-03-21
Active, closed
Astria Therapeutics, Inc.
Phase 3
157
Krakow, Lodz, Rzeszów, Warsaw
2025-03-20
Recruiting
Immunovant Sciences GmbH
Phase 2
162
Lublin, Bydgoszcz, Gdansk, Katowice, Krakow, Poznan, Warsaw
2025-03-18
Recruiting
AstraZeneca
Phase 3
990
Bialystok, Bydgoszcz, Chrzanów, Karczew, Katowice, Kielce, Krakow, Lodz
2025-03-18
Recruiting
Hoffmann-La Roche
Phase 3
600
??czna, ?ód?, Bia?ystok, Bydgoszcz, Chojnice, Karczew, Krakow, Nowy Targ
2025-03-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Poznan, Bydgoszcz, Krakow, Siedlce, Warsaw, Wieliszew, Bialystok, Gdynia
2025-03-16
Active, closed
Jerzy Hohendorff
Not applicable
30
Katowice, Krakow, Poznan
2025-03-11
Recruiting
Pfizer
Phase 3
723
Krakow, Oświęcim, Wroclaw, Lublin, Warsaw, Katowice
2025-03-11
Recruiting
UCB Biopharma SRL
Phase 3
40
Krakow, Sosnowiec
2025-03-11
Active, closed
Takeda
Phase 3
601
Bydgoszcz, Krakow, Wroclaw, Gdynia, Częstochowa, Elblag, Poznan, Warsaw
2025-03-10
Recruiting
BeOne Medicines
Phase 3
300
Krakow, Lodz, Lublin, Skorzewo, Wroclaw
2025-03-05
Recruiting
AstraZeneca
Phase 3
5,000
Bialystok, Gdynia, Gmina Świecie, Jasło, Katowice, Krakow, Lodz, Lublin
2025-03-03
Recruiting
Takeda
Phase 3
1,088
Poznan, Krakow, Katowice, Sochaczew, Warsaw, Opole, Bialystok, Bytom
2025-03-03
Recruiting
Incyte Corporation
Phase 3
600
Bialystok, Chorzów, Cracov, Gdansk, Gdynia, Grodzisk Mazowiecki, Katowice, Krakow
2025-02-28
Active, closed
A Phase 2 in Adult Subjects With Hereditary Angioedema
NCT06846398Hereditary Angioedema (HAE)
DrugBW-20805
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
25
Krakow
2025-02-28
Active, closed
AstraZeneca
Observational
105
Bydgoszcz, Bytom, Gdansk, Katowice, Krakow, Lodz, Lublin, Poznan
2025-02-28
Recruiting
Amgen
Phase 3
844
Poznan, Krakow, Wroclaw, Lublin, Warsaw, Wołomin, Malbork, Bydgoszcz
2025-02-25
Active, closed
Janssen Research & Development, LLC
Phase 3
552
Bialystok, Bydgoszcz, Elblag, Gdynia, Krakow, Lodz, Lublin, Nadarzyn
2025-02-21
Active, closed
Andrzej Frycz Modrzewski Krakow University
Not applicable
300
Krakow
2025-02-17
Recruiting
AbbVie
Phase 3
420
Poznan, Bydgoszcz, Krakow, Wroclaw, Warsaw
2025-02-13
Active, closed
Sanofi
Phase 3
231
Krakow, Wroclaw, Lublin, Warsaw, Bialystok
2025-02-12
Recruiting
Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants
NCT06823466Ischemic Stroke, Oral Anticoagulation, Atrial Fibrillation (AF), Outcome Assessment
University of L'Aquila
Observational
200
Krakow
2025-02-12
Active, closed
AbbVie
Phase 3
468
Poznan, Bydgoszcz, Krakow, Oświęcim, Wroclaw, Katowice
2025-02-10
Recruiting
Dianthus Therapeutics
Phase 3
256
Bydgoszcz, Krakow, Lodz, Lublin, Warsaw, Wroclaw
2025-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Lublin, Krakow, Bydgoszcz, Katowice, Lodz, Poznan, Skorzewo, Warsaw
2025-02-07
Active, closed
Genmab
Phase 3
584
Krakow, Bialystok, Gdansk, Lodz, Poznan, Siedlce, Szczecin
2025-02-07
Active, closed
Real-life Treatment Outcomes of Ravulizumab in PNH
NCT06633536Paroxysmal Nocturnal Haemoglobinuria
DrugRavulizumab
AstraZeneca
Observational
64
Bialystok, Brzozów, Bydgoszcz, Gdansk, Krakow, Lodz, Lublin, Opole
2025-02-06
Active, closed
Zura Bio Inc
Phase 2
80
Chorzów, Krakow, Lodz, Nowa Sól, Poznan, Warsaw, Zabrze
2025-02-06
Recruiting
Comparison of the Efficacy of Celiac Plexus Blockade, ESP and Lidocaine Infusion Under OFA
NCT06793527Regional Anaesthesia, Anesthesia and Analgesia
Jagiellonian University
Not applicable
300
Krakow
2025-02-06
Recruiting
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
NCT06651970Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
DrugAcalabrutinib
AstraZeneca
Phase 4
60
Krakow, Poznan
2025-02-04
Recruiting
Airway Therapeutics, Inc.
Phase 2/3
366
Gdansk, Krakow, Lodz, Poznan, Szczecin, Wroclaw
2025-02-03
Recruiting
Physio-Assist
Not applicable
468
Krakow, Lodz, Poznan
2025-02-03
Recruiting
Endo-ePIcardial Versus Endocardial Only Catheter Ablation for ISchemic Driven Ventricular Tachycardia (EPISODE VT)
NCT07240441Ventricular Tachycardias, Myocardial Infarction (MI), Implantable Cardiac Defibrillator, Ablation
MEDICOVER SP Z O.O.
Not applicable
220
Warsaw, Bydgoszcz, Gdansk, Krakow, Poznan, Szczecin
2025-02-03
Recruiting
BioNTech SE
Phase 3
621
Gdansk, Katowice, Konin, Koszalin, Krakow, Lodz, Lublin, Olsztyn
2025-02-03
By invitation
Pharvaris Netherlands B.V.
Phase 3
170
Krakow
2025-02-01
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Gdansk, Gliwice, Katowice, Konin, Krakow, Siedlce, Warsaw
2025-01-28
Recruiting
Adipokines in Polycystic Ovary Syndrome
NCT06793072PCOS, Reproductive Age
Jagiellonian University
Observational
300
Krakow
2025-01-20
Recruiting
Pro- and Anti-inflammatory Cytokines in PCOS
NCT06793085Reproductive Age, PCOS (Polycystic Ovary Syndrome)
Jagiellonian University
Observational
100
Krakow
2025-01-20
Recruiting
Functional Proteins in Polycystic Ovary Syndrome
NCT06793098Reproductive Age, PCOS (Polycystic Ovary Syndrome)
Jagiellonian University
Observational
100
Krakow
2025-01-20
Recruiting
Biogen
Phase 1
78
Krakow, Lodz
2025-01-16
Active, closed
argenx
Phase 3
631
Bialystok, Bydgoszcz, Częstochowa, Elblag, Gdynia, Grodzisk Mazowiecki, Katowice, Krakow
2025-01-15
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
DrugOcrelizumab
Amgen
Phase 3
152
Bydgoszcz, Katowice, Kielce, Krakow, Lodz, Lublin, Poznan, Warsaw
2025-01-13
Recruiting
GlaxoSmithKline
Phase 3
1,840
Bydgoszcz, Częstochowa, Krakow, Siemianowice Śląskie, Torun
2025-01-10
Active, closed
Janssen Research & Development, LLC
Phase 3
813
Bialystok, Bydgoszcz, Elblag, Gdynia, Krakow, Lodz, Lublin, Nadarzyn
2025-01-09
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Podlaski, Bydgoszcz, Wroclaw, Krakow, Sochaczew, Warsaw, Bialystok, Gdansk
2025-01-08
Recruiting
BioNTech SE
Phase 2/3
1,580
Bialystok, Bydgoszcz, Gdansk, Gliwice, Katowice, Kielce, Koszalin, Krakow
2025-01-07
Active, closed
Pfizer
Phase 3
1,035
Krakow, Bialystok, Gdynia, Koszalin, Lodz
2025-01-06
Recruiting
Loxo Oncology, Inc.
Phase 2
249
Bydgoszcz, Katowice, Krakow, Skórzewo, Wroclaw
2025-01-03
Not yet open
Diluted and Undiluted Enteral Nutrition
NCT06516835Critical Illness, Surgery, Enteral Feeding Intolerance, Gastro-Intestinal Disorder
Medical University of Lublin
Not applicable
60
Gorzów Wielkopolski, Krakow, Lublin, Opole
2025-01-02
Not yet open
Beta-blockade in Unruptured Intracranial Aneurysm
NCT06249802Intracranial Aneurysm
DrugNebivolol
Jagiellonian University
Phase 4
100
Krakow
2025-01-01
Recruiting
Cardiac Success
Not applicable
10
Krakow
2025-01-01
Recruiting
Supernus Pharmaceuticals, Inc.
Phase 2
216
Krakow, Warsaw, Gdynia, Sopot, Katowice, Lublin
2024-12-30
By invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543·Ibrutinib
Janssen Research & Development, LLC
Phase 1
120
Gdansk, Krakow, Skorzewo
2024-12-30
Recruiting
Cytokinetics
Phase 3
1,800
Warsaw, Bialystok, Krakow, Lodz, Miechów, Opole, Poznan, Ruda Śląska
2024-12-19
Active, closed
argenx
Phase 3
154
Bydgoszcz, Katowice, Krakow, Lublin, Warsaw
2024-12-18
Recruiting
Immunovant Sciences GmbH
Phase 2
240
Gliwice, Krakow, Lublin, Poznan, Warsaw
2024-12-17
Recruiting
Boehringer Ingelheim
Phase 2
80
Krakow, Lublin, Pabianice, Poznan, Rzeszów, Sopot, Szczecin, Torun
2024-12-11
Active, closed
Hoffmann-La Roche
Phase 3
350
?ód?, Bydgoszcz, Elblag, I?awa, Knurów, Krakow, Lublin, Poznan
2024-12-11
Active, closed
Amgen
Phase 3
707
Gdansk, Krakow
2024-12-09
Recruiting
Ryvu Therapeutics SA
Phase 2
178
Biała Podlaska, Bydgoszcz, Gdansk, Gdynia, Gliwice, Katowice, Krakow, Olsztyn
2024-12-05
Active, closed
PPM Services S.A.
Phase 3
400
Bialystok, Bydgoszcz, Chorzów, Częstochowa, Gdansk, Katowice, Krakow, Lodz
2024-12-05
Active, closed
Janssen Research & Development, LLC
Phase 3
655
Bydgoszcz, Dębica, Krakow, Lublin, Olsztyn, Poznan, Siedlce, Warsaw
2024-12-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,082
Poznan, Bydgoszcz, Krakow, Wroclaw, Warsaw, Gdynia, Bielsko-Biala, Katowice
2024-12-02
Active, closed
EyePoint Pharmaceuticals, Inc.
Phase 3
400
Bydgoszcz, Krakow, Lublin, Olsztyn, Tarnów, Warsaw
2024-11-27
Active, closed
Genmab
Phase 3
191
Koszalin, Krakow, Lodz, Skorzewo, Warsaw
2024-11-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,380
Poznan, Włocławek, Krakow, Wroclaw, Lublin, Warsaw, Katowice, Szczecin
2024-11-25
Recruiting
UCB Biopharma SRL
Phase 3
450
Katowice, Krakow, Lublin, Poznan, Warsaw, Wroclaw
2024-11-21
Recruiting
Eli Lilly and Company
Phase 3
125
Krakow, Lodz, Rzeszów, Stanisławów Pierwszy, Warsaw, Wroclaw
2024-11-18
Recruiting
EUthyroid
Not applicable
1,000
Krakow
2024-11-18
Recruiting
Eli Lilly and Company
Phase 3
150
Krakow, Warsaw, Warszewo, Wroclaw
2024-11-18
Recruiting
Predictors of Axial Pain Improvement After Anterior Cervical Discectomy and Fusion
NCT06601634Neck Pain, Cervical Spondylosis, Cervical Disc Disease
Medical University of Warsaw
Observational
60
Krakow, Warsaw
2024-11-17
Active, closed
Pfizer
Phase 3
636
Bydgoszcz, Krakow, Wroclaw, Lublin, Warsaw
2024-11-15
Active, closed
BeOne Medicines
Phase 2
94
Katowice, Krakow, Lublin, Wroclaw
2024-11-14
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Krakow, Lodz, Lublin, Mysłowice, Warsaw, Wroclaw
2024-11-12
Active, closed
argenx
Phase 2
87
Krakow, Lublin, Nowa Sól, Warsaw, Wroclaw
2024-11-11
Active, closed
Amgen
Phase 2
409
Bialystok, Krakow, Lublin, Staszów, Warsaw, Wroclaw
2024-11-07
Recruiting
Polish Version Fatigue Severity Scale
NCT06668649Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Stroke, Ischemic
Jakub Antczak
Observational
310
Krakow, Warsaw
2024-11-04
Recruiting
Artificial Intelligence in Colonoscopy
NCT06786793Quality Indicators, Health Care, Artificial Intelligence (AI), Colonoscopy Diagnostic Techniques and Procedures
Jagiellonian University
Not applicable
630
Krakow
2024-11-01
Active, closed
Angitia Biopharmaceuticals
Phase 2
379
Gdynia, Krakow, Lodz, Warsaw, Wroclaw
2024-10-31
Recruiting
Abivax S.A.
Phase 2
212
Bydgoszcz, Kielce, Knurów, Krakow, Lodz, Nowy Targ, Opole, Piotrkow Trybunalski
2024-10-30
Recruiting
Société des Produits Nestlé (SPN)
Not applicable
104
Bialystok, Bydgoszcz, Janki, Krakow, Lodz, Lublin, Rzeszów, Tarnów
2024-10-25
Active, closed
Amgen
Phase 3
19
Gdansk, Krakow, Warsaw
2024-10-22
Recruiting
Pfizer
Phase 3
900
Krakow, Wroclaw, Lublin, Warsaw, Koszalin, Opole, Piotrkow Trybunalski
2024-10-22
Active, closed
Pfizer
Phase 3
609
Grudziądz, Torun, Krakow, Wroclaw, Opole, Koszalin
2024-10-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Poznan, Krakow, Wroclaw, Warsaw, Przemyśl, Gdansk, Olsztyn, Kielce
2024-10-21
Active, closed
Novartis Pharmaceuticals
Phase 2
251
Krakow, Bydgoszcz, Warsaw
2024-10-17
Active, closed
MoonLake Immunotherapeutics AG
Phase 3
600
Bialystok, Bydgoszcz, Częstochowa, Elblag, Gdynia, Katowice, Krakow, Lodz
2024-10-15
Recruiting
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Observational
617
Krakow, Wroclaw
2024-10-14
Active, closed
Merck Sharp & Dohme LLC
Phase 2
66
Krakow, Warsaw, Gdansk, Gliwice
2024-10-14
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Krakow, Lodz, Lublin, Mysłowice, Warsaw, Wroclaw
2024-10-14
Active, closed
Incyte Corporation
Phase 3
349
Bialystok, Gdansk, Katowice, Krakow, Lublin, Pruszków, Szczecin, Warsaw
2024-10-10
Active, closed
Ipsen
Phase 2
670
Częstochowa, Katowice, Krakow, Lodz, Oświęcim, Pomorskie, Puławy, Siedlce
2024-10-10
Recruiting
Xencor, Inc.
Phase 1/2
270
Bydgoszcz, Katowice, Krakow, Nowy Targ, Sopot, Staszów, Szczecin, Warsaw
2024-10-10
Active, closed
Eli Lilly and Company
Phase 2
143
Bydgoszcz, Krakow, Lodz, Lublin, Opole, Poznan, Sopot, Torun
2024-10-10
Active, closed
AbbVie
Phase 2
309
Bydgoszcz, Katowice, Krakow, Lublin, Poznan, Warsaw
2024-10-07
Active, closed
AstraZeneca
Phase 3
768
Katowice, Krakow, Lodz, Olsztyn, Poznan
2024-10-04
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
Poznan, Krakow, Wroclaw, Lodz, Warsaw, Gdansk, Częstochowa, Katowice
2024-10-04
Recruiting
University Hospital, Geneva
Not applicable
220
Krakow
2024-10-01
Active, closed
Genmab
Phase 3
699
Bydgoszcz, Gdansk, Gliwice, Krakow, Lodz, Warsaw
2024-09-25
Recruiting
Parental Knowledge of First Aid for Choking and Cardiopulmonary Resuscitation in Infants Under One Year of Age
NCT06976463Choking in Infants, Cardiopulmonary Resuscitation (CPR), First Aid Training, Parental Knowledg
Andrzej Frycz Modrzewski Krakow University
Observational
100
Krakow
2024-09-19
Active, closed
H. Lundbeck A/S
Phase 1
20
Krakow, Katowice, Warsaw
2024-09-19
Active, closed
argenx
Phase 3
141
Bydgoszcz, Katowice, Krakow, Lublin
2024-09-18
Active, closed
Amgen
Phase 1
49
Gdansk, Gliwice, Krakow, Lodz, Lublin
2024-09-17
Recruiting
European Registry of Next Generation Imaging in Advanced Prostate Cancer
NCT06866782Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)
Fundacio Puigvert
Observational
600
Krakow
2024-09-17
Active, closed
Dianthus Therapeutics
Phase 2
46
Bydgoszcz, Katowice, Krakow
2024-09-17
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
190
Poznan, Krakow, Warsaw, Bydgoszcz, Lodz, Wroclaw
2024-09-17
Recruiting
Regeneron Pharmaceuticals
Phase 2
116
Torun, Wałbrzych, Krakow, Gdansk, Lodz, Kielce
2024-09-16
Active, closed
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
DrugsABP 234·Pembrolizumab
Amgen
Phase 3
163
Bydgoszcz, Lublin, Olsztyn, Krakow, Przemyśl, Sosnowiec
2024-09-12
Recruiting
AbbVie
Phase 2
590
Bydgoszcz, Torun, Krakow, Warsaw, Sopot, Tychy, Kielce
2024-09-04
Active, closed
Tectonic Therapeutic
Phase 2
191
Bialystok, Krakow, Lodz, Lublin, Warsaw, Wroclaw
2024-09-04
Active, closed
Takeda
Phase 3
2,099
Poznan, Krakow, Katowice, Kłodzko, Wroclaw, Lublin, Lódz, Nadarzyn
2024-09-04
Recruiting
Gossamer Bio USA, Inc.
Phase 3
330
Krakow, Otwock
2024-09-03
Recruiting
GlaxoSmithKline
Phase 1
142
Bydgoszcz, Krakow, Poznan, Warsaw, Wroclaw
2024-09-02
Recruiting
Dietary Macronutrients and Gut Microbiota, Inflammation, and Metabolic Markers
NCT07672691Nutrition, Ketogenic Diet, Gene Expression, Diet
The Jerzy Kukuczka Academy of Physical Education in Katowice
Not applicable
200
Krakow, Szczecin
2024-09-02
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Krakow, Lodzkie, Szczecin, Warsaw, Zamość
2024-08-30
Active, closed
Sanofi
Phase 2
229
Poznan, Krakow, Wroclaw, Warsaw
2024-08-29
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Bydgoszcz, Chojnice, Krakow, Lublin, Poznan, Sopot, Warsaw, Wroclaw
2024-08-28
Recruiting
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
NCT06351592Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Regeneron Pharmaceuticals
Phase 1/2
54
Krakow, Zabrze, Warsaw
2024-08-28
Active, closed
Regeneron Pharmaceuticals
Phase 4
120
Krakow, Wroclaw, Warsaw, Bialystok, Gdansk
2024-08-26
Recruiting
Colorado Prevention Center
Phase 3
2,600
Lublin, Oświęcim, Krakow, Lodz, Tychy
2024-08-20
Active, closed
AbbVie
Phase 3
699
Poznan, Torun, Krakow, Wroclaw, Warsaw, Bialystok, Katowice
2024-08-19
Recruiting
Jazz Pharmaceuticals
Phase 3
550
Bialystok, Biała Podlaska, Krakow, Poznan, Warsaw
2024-08-13
Active, closed
Genmab
Phase 3
379
Poznan, Krakow, Warsaw, Kielce
2024-08-13
Recruiting
AstraZeneca
Phase 3
620
Bialystok, Katowice, Krakow, Lublin, Warsaw, Wroclaw
2024-08-12
Recruiting
AstraZeneca
Phase 3
1,018
Gdansk, Gliwice, Katowice, Krakow, Lublin, Warsaw, Wroclaw
2024-08-07
Active, closed
EyeBiotech Ltd.
Phase 2/3
984
Gdansk, Bialystok, Bydgoszcz, Katowice, Krakow, Olsztyn, Tarnowskie Góry
2024-08-07
Active, closed
GlaxoSmithKline
Phase 3
10,212
Częstochowa, Elblag, Gdansk, Gdynia, Katowice, Krakow, Lodz, Poznan
2024-08-01
By invitation
AOP Orphan Pharmaceuticals AG
Observational
110
Krakow, Otwock
2024-07-31
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Lublin, Warsaw, Krakow, Katowice, Bydgoszcz, Poznan, Rzeszów
2024-07-31
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
982
Poznan, Bialystok, Bydgoszcz, Katowice, Krakow, Lodz, Szczecin, Świdnik
2024-07-31
By invitation
Medical University of Warsaw
Phase 2/3
114
Krakow, Poznan, Warsaw
2024-07-30
Active, closed
Celldex Therapeutics
Phase 3
976
Częstochowa, Elblag, Gdansk, Grodzisk Mazowiecki, Katowice, Krakow, Lodz, Lublin
2024-07-19
Recruiting
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
385
Bydgoszcz, Częstochowa, Elblag, Gdansk, Katowice, Krakow, Kłodzko, Opole
2024-07-18
Active, closed
Vor Biopharma
Phase 3
191
Poznan, Bydgoszcz, Krakow, Lublin, Nowa Sól, Warsaw, Gdansk, Katowice
2024-07-17
Recruiting
Heidelberg University
Observational
4,000
Krakow
2024-07-16
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Krakow, Lublin, Rzeszów
2024-07-12
Active, closed
Celldex Therapeutics
Phase 3
963
Bialystok, Bydgoszcz, Elblag, Gdansk, Katowice, Kielce, Krakow, Lodz
2024-07-11
Active, closed
GRIN Therapeutics, Inc.
Phase 1/2
30
Gdansk, Krakow, Poznan, Warsaw
2024-07-10
Active, closed
Novartis Pharmaceuticals
Phase 2
155
Krakow, Lublin
2024-07-02
Active, closed
AbbVie
Phase 3
1,400
Bydgoszcz, Krakow, Warsaw, Katowice, Lodz
2024-06-27
Active, closed
Genmab
Phase 3
621
Bydgoszcz, Gdansk, Gliwice, Krakow, Lodz, Poznan, Warsaw
2024-06-25
Recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Gdansk, Krakow, Warsaw, Zabrze
2024-06-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Bydgoszcz, Krakow, Warsaw, Wieliszew, Bialystok, Gdynia, Gliwice, Szczecin
2024-06-24
Active, closed
Sanofi
Phase 2
185
Warsaw, Krakow
2024-06-20
Recruiting
AstraZeneca
Phase 3
240
Bialystok, Krakow, Lodz, Poznan, Warsaw, Wroclaw
2024-06-20
Active, closed
H. Lundbeck A/S
Phase 2
16
Krakow
2024-06-19
Active, closed
Celgene
Phase 3
850
Skórzewo, Bydgoszcz, Krakow, Lublin, Warsaw, Katowice
2024-06-19
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Bydgoszcz, Grudziądz, Gorlice, Krakow, Poznań, Lublin, Warsaw, Przemyśl
2024-06-10
Recruiting
LEO Pharma
Phase 3
195
Gdansk, Krakow, Lodz, Ostrowiec Świętokrzyski, Rzeszów, Tarnów, Warsaw
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Poznan, Bydgoszcz, Torun, Krakow, Nowy Targ, Oświęcim, Jelenia Góra, Wroclaw
2024-06-05
Recruiting
Kartos Therapeutics, Inc.
Phase 3
600
Bialystok, Gdansk, Krakow, Lodz, Nowy Sącz, Olsztyn, Poznan, Szczecin
2024-06-03
Active, closed
Janssen Research & Development, LLC
Phase 2
333
Biała Podlaska, Brzozów, Gdynia, Kielce, Krakow, Lodz, Lublin
2024-05-30
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
Hoffmann-La Roche
Phase 3
1,800
Katowice, Krakow, Lodz, Mysłowice, Warsaw, Wroclaw
2024-05-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Gorlice, Krakow, Lublin, Warsaw, Przemyśl, Olsztyn
2024-05-24
Recruiting
Jakub Antczak
Not applicable
90
Krakow
2024-05-20
Recruiting
NMD Pharma A/S
Phase 2
84
Katowice, Krakow, Lublin, Myślenice, Warsaw
2024-05-16
Active, closed
Biohaven Therapeutics Ltd.
Phase 2/3
390
Krakow, Warsaw, Wroclaw
2024-05-13
Active, closed
Sanofi
Phase 3
1,541
Krakow, Tarnów, Lublin, Lodz, Warsaw, Gdansk, Katowice
2024-05-08
Recruiting
University School of Physical Education, Krakow, Poland
Not applicable
60
Krakow
2024-05-07
Active, closed
Hoffmann-La Roche
Phase 2
256
?ory, Bia?ystok, Bydgoszcz, Katowice, Krakow, Sopot, Szczecin, Warsaw
2024-05-02
Active, closed
Eli Lilly and Company
Phase 3
10,000
Bialystok, Bielsko-Biala, Bydgoszcz, Chorzów, Chrzanów, Elblag, Gdansk, Krakow
2024-04-30
By invitation
Travere Therapeutics, Inc.
Phase 3
100
Krakow, Warsaw
2024-04-30
Recruiting
Eli Lilly and Company
Phase 3
510
Bialystok, Katowice, Kielce, Krakow, Poznan, Warsaw, Wieliczka, Wroclaw
2024-04-29
Active, closed
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
470
Wroclaw, Lublin, Warsaw, Gdansk, Katowice, Sosnowiec, Szczecin, Krakow
2024-04-29
Recruiting
Opioid-free Anesthesia as an Alternative to General Anesthesia in Abdominal Surgery
NCT06380244Analgesics, Opioid, Anesthesia, Endotracheal, Anesthesia, General
Jagiellonian University
Not applicable
600
Krakow
2024-04-29
Active, closed
Eli Lilly and Company
Phase 3
450
Kielce, Krakow, Lodz, Lublin, Piła, Rzeszów, Skierniewice, Tarnów
2024-04-26
Active, closed
Amgen
Phase 3
111
Krakow, Lodz, Rzeszów, Tychy
2024-04-22
Active, closed
argenx
Phase 3
119
Bydgoszcz, Katowice, Krakow, Lublin, Wroclaw
2024-04-16
Active, closed
Celldex Therapeutics
Phase 2
140
Krakow, Gdynia, Katowice, Lublin, Rzeszów, Warsaw, Wroclaw
2024-04-12
Recruiting
Daiichi Sankyo
Phase 1/2
680
Krakow, Lodz, Rzeszów, Siedlce, Skorzewo
2024-04-10
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Bialystok, Bydgoszcz, Krakow, Lublin, Przemyśl, Tarnów, Torun, Wieliszew
2024-04-09
Active, closed
Amgen
Phase 3
434
Krakow, Wroclaw, Lublin, Warsaw, Wołomin, Malbork, Bydgoszcz, Katowice
2024-04-08
Active, closed
Jagiellonian University
Not applicable
35
Krakow
2024-04-04
Active, closed
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
DrugPirfenidone
Avalyn Pharma Inc.
Phase 2
398
Bydgoszcz, Krakow, Lodz
2024-04-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Poznan, Krakow, Lublin, Warsaw, Przemyśl, Bialystok, Gdansk, Prabuty
2024-04-03
Active, closed
Novo Nordisk A/S
Phase 3
673
Bydgoszcz, Włocławek, Krakow, Oświęcim, Jelenia Góra, Wroclaw, Puławy, Żyrardów
2024-04-01
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Bialystok, Krakow, Lodz, Lublin, Olsztyn, Poznan, Szczecin, Warsaw
2024-03-29
Active, closed
AstraZeneca
Phase 3
2,554
Chrzanów, Gdynia, Krakow, Lodz, Lublin, Olsztyn, Poznan, Rzeszów
2024-03-29
Active, closed
Gilead Sciences
Phase 2
228
Bydgoszcz, Katowice, Krakow, Ksawerów, Lublin, Mazowieckie, Poznan, Rzeszów
2024-03-27
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
Hoffmann-La Roche
Phase 3
1,350
Katowice, Krakow, Lodz, Mysłowice, Warsaw, Wroclaw
2024-03-13
Active, closed
Janssen Research & Development, LLC
Phase 3
731
Bialystok, Katowice, Kielce, Krakow, Olsztyn, Warsaw, Wroclaw
2024-03-09
Recruiting
Clinical Application of the J-PET Scanner Prototype
NCT06242119Prostate Cancer, Prostatic Hyperplasia, Prostatic Neoplasms, Prostate Cancer Metastatic
Jagiellonian University
Observational
25
Krakow
2024-03-07
Active, closed
AstraZeneca
Phase 3
594
Bielsko-Biala, Gdansk, Katowice, Krakow, Lublin, Słupsk, Warsaw
2024-03-04
Active, closed
Dianthus Therapeutics
Phase 2
65
Bydgoszcz, Katowice, Krakow, Lublin, Warsaw
2024-02-23
Active, closed
Genmab
Phase 3
1,095
Poznan, Krakow, Warsaw, Lodz, Kielce
2024-02-05
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Gdansk, Katowice, Krakow, Lodz, Torun, Warsaw, Wałbrzych
2024-02-05
Active, closed
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
DrugAdagrasib
Mirati Therapeutics Inc.
Phase 2
200
Krakow, Gdynia, Lublin
2024-02-01
Active, closed
DualityBio Inc.
Phase 3
541
Rzeszów, Torun, Krakow, Poznan, Warsaw, Wroclaw, Lodz
2024-01-18
Active, closed
Janssen Research & Development, LLC
Phase 3
774
Bialystok, Elblag, Krakow, Lodz, Osielsko, Poznan, Warsaw, Wroclaw
2024-01-17
Recruiting
Colorado Prevention Center
Phase 3
5,200
Katowice, Krakow, Lodz, Lublin, Oświęcim, Tychy
2024-01-17
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
98
Krakow, Warsaw
2024-01-16
Recruiting
Multimodal Cardiac Imaging Registry in Patients with Atrial Fibrillation
NCT06584266Atrial Fibrillation and Flutter, Heart Failure, Artificial Intelligence (AI), Echocardiography
University in Zielona Góra
Observational
3,000
Nowa Sól, Katowice, Krakow, Warsaw, Zielona Góra
2024-01-01
Recruiting
Travere Therapeutics, Inc.
Phase 3
70
Krakow, Warsaw
2023-12-28
Recruiting
Regeneron Pharmaceuticals
Phase 3
580
Bydgoszcz, Wałbrzych, Wroclaw, Lublin, Krakow, Gdansk, Poznan, Skorzewo
2023-12-28
Active, closed
Sanofi
Phase 3
943
Poznan, Bydgoszcz, Krakow, Rzeszów, Bialystok, Katowice, Zabrze
2023-12-27
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential
Orchestra BioMed, Inc
Not applicable
316
Katowice, Krakow, Lodz, Lublin, Poznan, Szczecin, Warsaw, Wroclaw
2023-12-27
Recruiting
Ascentage Pharma Group Inc.
Phase 3
400
Bydgoszcz, Krakow, Lodz, Skorzewo
2023-12-20
Active, closed
AbbVie
Phase 3
614
Osielsko, Krakow, Warsaw, Bialystok, Katowice, Szczecin
2023-12-19
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Bydgoszcz, Grudziądz, Torun, Krakow, Warsaw, Przemyśl, Olsztyn, Lodz
2023-12-15
Recruiting
Regeneron Pharmaceuticals
Phase 3
904
Krakow, Wroclaw, Poznan, Skorzewo, Bydgoszcz, Gdansk, Lublin, Warsaw
2023-12-13
Rows per page Showing 1–500 of 881
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-poland/city/krakow

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,709 studies in total at the last sync on 12 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 881 of those studies with a site in Krakow.

How many clinical trials are recruiting in Krakow?

446 of the 881 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:19 UTC sync. A further 17 have not yet opened recruitment, 394 are active but closed to new participants, and 24 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Krakow), 881 studies
PhaseStudiesRecruitingShare
Phase 350422657.2%
Phase 21546517.5%
Observational63497.2%
Not applicable57406.5%
Phase 2/335244%
Phase 127153.1%
Phase 1/224172.7%
Phase 417101.9%

Most active sponsors

Lead sponsors with the most studies (Krakow)
Lead sponsorStudiesRecruiting
AstraZeneca7035
Eli Lilly and Company4026
Hoffmann-La Roche3918
Janssen Research & Development, LLC378
Merck Sharp & Dohme LLC3623
Jagiellonian University3225
Pfizer3021
AbbVie256
Novartis Pharmaceuticals2110
Sanofi217
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.